Quality of life in patients (pts) with Relapsed and Refractory Multiple Myeloma (RRMM) treated with the BCMA-DIRECTED CAR T cell therapy Idecabtagene Vicleucel (IDE-CEL, bb2121): Results from the KarMMa trial

被引：0
|
作者：
Weisel, K. [1 ]
Einsele, H. [2 ]
Goldschmidt, H. [3 ,4 ]
Delforge, M. [5 ]
San Miguel, J. [6 ]
Bertin, K. B. [7 ]
Tahir, M. [7 ]
Lewis, H. [8 ]
Wang, J. [9 ]
Braverman, J. [9 ]
Campbell, T. B. [9 ]
Munshi, N. [10 ,11 ,12 ]
机构：
[1] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany
[2] Univ Hosp Wurzburg, Wurzburg, Germany
[3] Univ Hosp Heidelberg, Internal Med 5, Heidelberg, Germany
[4] Univ Hosp Heidelberg, Natl Ctr Tumor Dis NCT, Heidelberg, Germany
[5] Univ Hosp Leuven, Leuven, Belgium
[6] Univ Navarra Clin, Pamplona, Spain
[7] ICON Plc, San Francisco, CA USA
[8] ICON Plc, London, England
[9] Bristol Myers Squibb, Princeton, NJ USA
[10] Harvard Med Sch, Boston, MA 02115 USA
[11] Dana Farber Canc Inst, LeBow Inst Myeloma Therapeut, Boston, MA 02115 USA
[12] Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2020年 / 43卷 / SUPPL 4期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
214
引用
收藏
页码：93 / 94
页数：2
相关论文
共 50 条
  • [41] Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma
    Anderson, Larry D., Jr.
    FUTURE ONCOLOGY, 2021, 18 (03) : 277 - 289
  • [42] A Matching-Adjusted Indirect Comparison of Efficacy Outcomes for Idecabtagene Vicleucel (ide-cel, bb2121), a Bcma-Directed CAR T Cell Therapy Versus Conventional Care in Triple-Class-Exposed Relapsed and Refractory Multiple Myeloma
    Shah, Nina
    Ayers, Dieter
    Davies, Faith E.
    Cope, Shannon
    Mojebi, Ali
    Parikh, Kejal
    Dhanda, Devender
    Hari, Parameswaran
    Patel, Payal
    Huang, Liping
    Hege, Kristen
    Dhanasiri, Sujith
    BLOOD, 2020, 136
  • [43] Matching-adjusted indirect comparison of efficacy outcomes for Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy, versus conventional care in triple-class-exposed relapsed and refractory multiple myeloma
    Goldschmidt, H.
    Shah, N.
    Ayers, D.
    Davies, F.
    Cope, S.
    Mojebi, A.
    Dhanda, D.
    Hari, P.
    Patel, P.
    Huang, L.
    Hege, K.
    Dhanasiri, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 205 - 206
  • [44] HEALTHCARE RESOURCE UTILIZATION AND 2022 COST UPDATE OF CYTOKINE RELEASE SYNDROME AND NEUROTOXICITY IN PATIENTS WITH RELAPSED/ REFRACTORY MULTIPLE MYELOMA (RRMM) RECEIVING IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121) IN KARMMA
    McGarvey, N.
    Imanak, K.
    Carattini, T.
    Ung, B.
    Campbell, T. B.
    Gitlin, M.
    Patwardhan, P.
    VALUE IN HEALTH, 2023, 26 (06) : S89 - S89
  • [45] IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121) IN MULTIPLE RECALL/REFRACTORY MYELOMA (MMRR): ANALYSIS OF HIGH-RISK PATIENT SUBGROUPS (PTS) FROM THE KARMMA STUDY
    Jesus, San-Miguel
    Noopur, Raje S.
    David, Siegel
    Sundar, Jagannath
    Sagar, Lonial
    Nikhil, Munshi C.
    Philippe, Moreau
    Hartmut, Goldschmidt
    Michele, Cavo
    Anna, Truppel-Hartmann
    Everton, Rowe
    Huang Liping
    Amit, Agarwal
    Julie, Wang
    Timothy, Campbell B.
    Donna, Reece E.
    HAEMATOLOGICA, 2021, 106 (10) : 77 - 77
  • [46] CHARACTERISTICS OF NEUROTOXICITY ASSOCIATED WITH IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121) IN PATIENTS WITH MULTIPLE MYELOMA IN RECALLING AND REFRACTORY OF THE PIVOTAL STUDY PHASE 2 KARMMA
    Albert, Oriol
    Salomon, Manier
    Ankit, Kansagra
    Larry, Anderson Jr D.
    Jesus, Berdeja
    Sundar, Jagannath
    Yi, Lin
    Sagar, Lonial
    Nina, Shah
    Noopur, Raje
    David, Siegel
    Anna, Truppel-Hartmann
    Everton, Rowe
    Payal, Patel
    Amit, Agarwal
    Timothy, Campbell B.
    Paula, Rodriguez-Otero
    Nikhil, Munshi
    HAEMATOLOGICA, 2021, 106 (10) : 78 - 79
  • [47] Estimation of Long-Term Post-Infusion Costs of Care for Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Following Administration of Idecabtagene Vicleucel (ide-cel, bb2121) in the KarMMa Clinical Trial
    McGarvey, November
    Carattini, Thomas
    Ung, Brian
    Campbell, Timothy B.
    Imanak, Ken
    Patwardhan, Pallavi
    BLOOD, 2022, 140 : 10947 - 10948
  • [48] EFFECTIVENESS AND SAFETY OF IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121) IN OLDER PATIENTS WITH MULTIPLE RECRACING / REFRACTORY MYELOMA (MMRR): SUBGROUP ANALYSIS OF THE KARMMA STUDY
    Paula, Rodriguez-Otero
    Jesus, Berdeja
    Noopur, Raje
    David, Siegel
    Yi, Lin
    Larry, Anderson D.
    Salomon, Manier
    Hermann, Einsele
    Michele, Cavo
    Anna, Truppel-Hartmann
    Everton, Rowe
    Jill, Sanford
    Julie, Wang
    Timothy, Campbell B.
    Sundar, Jagannath
    HAEMATOLOGICA, 2021, 106 (10) : 76 - 76
  • [49] Healthcare resource utilization and economic burden of cytokine release syndrome (CRS) and neurologic events (NE) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) receiving idecabtagene vicleucel (ide-cel, bb2121) in KarMMa.
    Hari, Parameswaran
    Nguyen, Andy
    Pelletier, Corey
    McGarvey, November
    Gitlin, Matthew
    Parikh, Kejal
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (29)
  • [50] The B Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor (CAR) T Cell Therapy Idecabtagene Vicleucel (Ide-Cel; Bb2121) in Relapsed and Refractory Multiple Myeloma (Rrmm): Outcomes from a Phase 1 Study Support the Phase 3 Karmma-3 Study Design to Compare IDE-Cel Versus Standard Triplet Regimens
    Einsele, Hermann
    Raab, Marc
    Kroeger, Nicolaus
    Fenk, Roland
    Scheid, Christoph
    Munshi, Nikhil
    Petrocca, Fabio
    Hege, Kristen
    Novick, Steven
    Raje, Noopur
    Kochenderfer, James
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 213 - 213
12345